1789 TT

ScinoPharm Investor Conference

— 2025 12 11

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Company Overview

02 Business Update

03 Financial Performance



Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/cGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and cGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 79 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 976 active DMFs worldwide with 70 US DMFs*
- 200+ contract projects with 14 approved/launched (12 NCEs) and 4 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority. In November 2024, we passed Brazilian ANVISA 1st on-site GMP inspection with zero defect and maintained its exceptional track record of 5 consecutive zero defect inspections by the US FDA
- Injectable plant certified by US FDA and TFDA

*Data As of 2025/10/31



Business Update

Strengthening API Business

- **As of October 2025, 2 new oncology products have completed DMF registration, bringing the total to 79 developed generic APIs with DMFs filed, of which 37 are already being supplied to customers for commercial sales.**
- **Maintain existing market share, and continuously develop new customers and explore new markets, such as China, Europe, and South America, to expand our global presence.**
- **Keep developing new generic APIs to enrich our pipeline, currently multiple new APIs being developed.**



Accelerating Drug Product Business Development

- Continue to expand the injectable drug product pipeline, accelerate the approval of proprietary injectable products in the US and prepare for US market launch.
- Proactively seeking strategic partnerships to expand beyond the US and capture growth opportunities in markets such as Canada, Australia, Japan, China, and Europe.
- Submitted oncology and diabetes injectable products to the TFDA for approval, paving the way for entry into the Taiwan market.

Dosage Form	Project Numbers	Indication	Under Development	Technical Package Ready	Dossier Ready	Under Registration	Approved
Lyophilized Powder	5	• Myelodysplastic Syndromes • Multiple Myeloma • Oncology	1	1 1			1 1
Liquid Solution	7	• Leukemia • Oncology • Reversal of Neuromuscular Blockade • Multiple Myeloma	1	4 1			1
Prefilled Syringe	3	• Thromboembolic Disorders • Multiple Sclerosis • Medical Imaging Agents		1		1#	1
Cartridge in Device	5	• Osteoporosis • Diabetes Mellitus • Chronic Weight Management	1	1	1	1* 1#	

- 2 products under development were added to injectable drug product portfolio as of October 2025
- # Responded to FDA CRL / * Preparing for response to FDA CRL

Expanding CDMO Services

- Continue to expand our global CDMO presence and grow our CDMO services.
- Focusing on specialized areas such as peptides, steroids, and cytotoxic products, and leveraging our strengths in the development and manufacturing capabilities in both APIs and injectable DPs to provide customers with one-stop comprehensive services, striving to become a collaborative partner for global pharmaceutical companies in APIs and injectable DPs contract manufacturing.



➢ 2 projects at R&D pre-clinical stage and 1 project at phase I stage were added to API CDMO projects portfolio as of October 2025

* Another project at R&D pre-clinical stage was added in Nov. 2025, total number of API CDMO projects will accumulate to 13

Actively Develop Business in China

- SciAnda Changshu proactively expand the API customer base and strengthen collaborations with Chinese pharmaceutical companies to gradually grow our business in China.
- SciAnda Changshu continues to leverage its API development capabilities to enrich its product pipeline, submit more generic API regulatory filings in 2025 progressively. These efforts aim to meet domestic market demands in China, expand into international markets, and aggressively grow our CDMO service.
- As of October 2025, SciAnda Changshu passed one more GMP inspection by the Chinese authority, bringing the total to 6 products that have successfully passed GMP inspections, with preparations underway for commercial supply to customers in line with their product launches.
- In October 2025, Olaparib, a cancer drug of our client, was selected through China's volume-based procurement, injecting momentum into the future operations of SciAnda Changshu.



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	3Q 2025		YoY	3Q 2024	
Revenue	2,155	100%	-9%	2,370	100%
Gross Profit	763	36%	-17%	923	39%
Operating Expenses	(662)	(31%)	-1%	(668)	(28%)
Operating Profit	101	5%	-60%	255	11%
Net Profit before Tax	123	6%	-59%	299	13%
Net Profit after Tax	96	5%	-60%	242	10%
EPS (NTD)	0.12	-	-	0.31	-

Sales Distribution – By Business





Note：Statistics will be listed and presented using a new classification method starting in 2024

Unit: USD/M

	API	CDMO	Drug Product
3Q 2025 Sales	47.9	21.2	0
YoY	-9.7%	6.1%	-100.0%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
3Q 2025 Sales	45.8	15.6	7.7
YoY	-2.5%	-11.2%	-19.1%

Consolidated Balance Sheet

NTD Million	2025/09/30		2024/09/30	
Cash and Cash Equivalents	2,851	23%	3,976	34%
Accounts Receivable	379	3%	446	4%
Inventories	1,904	16%	1,877	16%
Property, Plant & Equipment	3,423	28%	3,702	32%
Financial Assets	1,952	16%	74	1%
Other Current/Non-Current Assets	1,803	14%	1,709	13%
Total Assets	**12,312**	**100%**	**11,784**	**100%**
Financial Debt	140	1%	36	0%
Other Current Liabilities	550	5%	658	6%
Other Non-Current Liabilities	629	5%	650	5%
Total Liabilities	**1,319**	**11%**	**1,344**	**11%**
Total Shareholders' Equities	**10,993**	**89%**	**10,440**	**89%**

Consolidated Cash Flow Statement

NTD million	3Q 2025	3Q 2024	Dif.
From Operating Activities	**252**	**496**	**-244**
Depreciation & Amortization	385	365	20
From Investing Activities	**(1,369)**	**(234)**	**-1,135**
Acquisition of financial assets	(1,156)	-	-1,156
Capital Expenditure	(214)	(241)	-27
From Financing Activities	**(182)**	**(242)**	**60**
Effect of foreign exchange rate changes	(16)	14	-30
Net Change in Cash	**(1,315)**	**34**	**-1,349**
Beginning Balance	4,166	3,942	224
Ending Balance	**2,851**	**3,976**	**-1,125**



Q & A

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT